100 Clinical Results associated with H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

100 Translational Medicine associated with H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

100 Patents (Medical) associated with H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

Literatures (Medical) associated with H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

15 May 2011·TransplantationQ2 · MEDICINE

Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients

Q2 · MEDICINE

Article

Author: Brunhilde Schweiger ; Tobias Deuse ; Hermann Reichenspurner ; Edgar Sattinger ; Angelika Costard-Jäckle ; Michael Schlüter ; Sven Meyer ; Christine Eulenburg ; Corina Ilchmann ; Hendrik Runte ; Matti Adam

BACKGROUNDInfluenza A (H1N1) has emerged as a considerable threat for recipients of organ transplants. Vaccination against the novel influenza A (H1N1) virus has generally been advocated. There is limited experience with AS03-adjuvanted A/H1N1 pandemic influenza vaccines in immunosuppressed patients.METHODSWe conducted an observational, nonrandomized single-center study to assess antibody response and vaccine-related adverse effects in 47 heart transplant recipients (44 men; age, 56±13 years). The AS03-adjuvanted, inactivated split-virion A/California/7/2009 H1N1v pandemic vaccine was administered. Antibody titers were measured using hemagglutination inhibition; immunoglobulin G (IgG) response was assessed using a new pandemic influenza A IgG enzyme-linked immunosorbent assay (ELISA) test kit and compared with hemagglutination-inhibition titers. Adverse effects of vaccination were assessed by a questionnaire.RESULTSPostvaccination antibody titers of greater than or equal to 1:40 were found in only 15 patients, corresponding to a seroprotection rate of 32% (95% confidence interval, 19%-47%). Sensitivity, specificity, positive predictive value, and negative predictive value of ELISA testing were 80.0%, 68.8%, 54.5%, and 88.0%, respectively. Age, time posttransplantation, and immunosuppressive regimen did not impact antibody response. Vaccination was well tolerated.CONCLUSIONSSingle-dose administration of an AS03-adjuvanted vaccine against the novel influenza A (H1N1) virus did not elicit seroprotective antibody concentrations in a substantial proportion of heart transplant recipients; the new pandemic influenza A IgG ELISA test kit proved to be of limited clinical use.

100 Deals associated with H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

H1N1 influenza A vaccine (SPLIT Virion, Inactivated)(Changchun Longevity Biological Technology Limited Liability Company)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation